Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications. While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. It was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Alredase, Tolrestatum, Lorestat and Alrestin. Its PubChem CID is 53359.
Tolrestat
| CAS No | 82964-04-3 |
|---|---|
| Molecular Formula | C16H14F3NO3S |
| Molecular Weight | 357.3 g/mol |
| Synonyms | 2-[[6-methoxy-5-(trifluoromethyl)naphthalene-1-carbothioyl]-methylamino]acetic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications. S. due to toxicity and never received FDA approval.
The listed CAS number is 82964-04-3.
The listed molecular formula is C16H14F3NO3S.
The listed molecular weight is 357.3 g/mol.
2-[[6-methoxy-5-(trifluoromethyl)naphthalene-1-carbothioyl]-methylamino]acetic acid.
The source lists Alredase, Tolrestatum, Lorestat and Alrestin.